Long-term data from the DanGer Shock randomized controlled trial (RCT) confirms the sustained survival benefits of Johnson & Johnson‘s Impella CP heart pump in patients with cardiogenic shock after a heart attack. The findings, presented at the European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine (NEJM), demonstrate a significant impact on patient outcomes.
Researchers found that over a decade, patients using Impella CP experienced a 16.3% lower mortality rate compared to those receiving standard care. This represents a considerable improvement over the initial six-month data, which showed a 12.7% reduction in mortality. The study also revealed that Impella CP patients gained an average of 600 additional days of life.
Jacob Møller, the principal investigator of the DanGer Shock trial, highlighted the trial’s validation of the Impella CP‘s long-term efficacy. Navin Kapur, chief medical and scientific officer for heart recovery at J&J MedTech, emphasized that the survival benefit is not only present but also increases over time.
The DanGer Shock RCT, conducted between 2013 and 2023, involved 360 participants across 14 sites in Denmark, Germany, and the United Kingdom. The study’s results led to the American College of Cardiology (ACC) and American Heart Association (AHA) upgrading Impella‘s guideline classification.
Cardiogenic shock, a life-threatening complication of heart attacks, affects a significant number of patients annually. The Impella CP device, a small heart pump, temporarily assists the heart’s pumping function, enabling it to rest and recover while maintaining blood flow. This allows patients to potentially return to a normal life with their own heart.
Johnson & Johnson‘s cardiovascular solutions portfolio focuses on addressing significant unmet needs in heart health, including heart failure, coronary artery disease, stroke, and atrial fibrillation. The company aims to lead in heart recovery, circulatory rest
Related
